苑东生物 (688513)
Chengdu Easton Biopharmaceuticals Co., Ltd.
K-Line Chart
No K-line data available
Company NameChengdu Yuandong Biopharmaceutical Co., Ltd.
Listing Date2020-09-02
Issue Price44.36RMB
Registered Capital17653.225610k RMB
Legal RepresentativeWang Ying
Registered AddressNo. 8 Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, production, and sales of chemical raw materials and chemical drug preparations.
Company ProfileChengdu Yuandong Biopharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise integrating the entire industry chain of drug R&D, production, and sales. The company possesses strong capabilities in industrializing R&D achievements, enabling independent realization of drug R&D, production, and sales. It owns GMP production lines for chemical drug preparations (such as capsules, tablets, and injections) and chemical raw materials. The company boasts an efficient, professional, and dynamic team. The discipline leaders in the R&D center all hold doctoral degrees. The company has established a provincial-level enterprise technology center and a postdoctoral workstation, and employs talents recognized at various levels, including the National 'Ten Thousand Talents Plan' and the Provincial 'Thousand Talents Plan'. The company's R&D team is recognized as a top-tier innovation team in Sichuan Province by the Organization Department of the Sichuan Provincial Party Committee. The heads of the production and quality systems are domestic GMP experts and technical experts with extensive experience in EU/FDA GMP certification.
Stock Details
1. Key Indicators
- Total Shares(W): 17653.23
- Circulating A-Shares(W): 17653.23
- Earnings Per Share(RMB): 1.2500
- Net Assets Per Share(RMB): 16.2349
- Operating Revenue(W RMB): 101913.36
- Total Profit(W RMB): 24208.98
- **Net Profit Attributable to Parent(W RMB) **: 22016.25
- Net Profit Growth Rate(%): 1.45
- Weighted Return on Equity(%): 7.9300
- Operating Cash Flow Per Share(RMB): 1.2400
- Undistributed Profit Per Share(RMB): 7.2264
- Capital Reserve Per Share(RMB): 7.9293
2. Main Business
The main business covers:
- Research, production, and sales of chemical raw materials and chemical drug preparations
3. Company Basic Information
- Company Name: Chengdu Easton Biopharmaceuticals Co., Ltd.
- Listing Date: 2020-09-02
- Industry: Pharmaceutical Manufacturing
- Address: No. 8 Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province
- Website: https://www.eastonpharma.cn
- Company Profile: The company was established by converting Easton Co., Ltd. into a joint stock company. In December 2015, Zhonghui Accounting Firm was commissioned to audit the net assets of Easton Co., Ltd. as of the base date of September 30, 2015, and issued an audit report. The audited net asset value of Easton Co., Ltd. as of September 30, 2015, was RMB 220.2926 million. In December 2015, Tianyuan Asset Appraisal Co., Ltd. was commissioned to appraise the net assets of Easton Co., Ltd. as of the base date of September 30, 2015, and issued an asset appraisal report. The appraised net asset value of Easton Co., Ltd. as of September 30, 2015, was RMB 273.2308 million. In December 2015, Easton Co., Ltd. held a shareholders' meeting, which reviewed and unanimously passed a resolution to legally convert Easton Co., Ltd. into a joint stock company with the 15 shareholders of Easton Co., Ltd. as joint promoters, based on the date of September 30, 2015. The registered capital of Easton Biopharmaceuticals was based on the audited net asset value of Easton Co., Ltd. of RMB 220.2926 million as of September 30, 2015, converted into 86.5 million shares of Easton Biopharmaceuticals, with a par value of RMB 1.00 per share. After the conversion, the registered capital (total share capital) of Easton Biopharmaceuticals was RMB 86.5 million, and the balance of the net assets after deducting the share capital, RMB 133.7926 million, was included in the capital reserve. The above conversion matters were verified by Zhonghui Accounting Firm. In December 2015, Easton Biopharmaceuticals completed the industrial and commercial change registration procedures for the above matters.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Chengdu Nanyuan Investment Partnership (Limited Partnership) | General Legal Person | 512.95 | 2.91 |
| 2 | Guotai Jiatai Stock Special Pension Product - China Merchants Bank Co., Ltd. | Asset Management Plan | 220.37 | 1.25 |
| 3 | Bosera Research Preferred Flexible Allocation Hybrid Securities Investment Fund (LOF) Class A | Fund | 163.51 | 0.93 |
| 4 | Great Wall Pharmaceutical Industry Selected Hybrid Initiation Securities Investment Fund Class A | Fund | 162.21 | 0.92 |
| 5 | Industrial Health Care Hybrid Securities Investment Fund Class A | Fund | 48.18 | 0.27 |
| 6 | Bosera Value Selection Two-Year Holding Period Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 34.14 | 0.19 |
| 7 | Puyin Ansheng Value Growth Hybrid Securities Investment Fund Class A | Fund | 30.21 | 0.17 |
| 8 | Puyin Ansheng Health Care Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 26.48 | 0.15 |
| 9 | Hongtu Innovation Health Care Stock Initiation Securities Investment Fund | Fund | 23.83 | 0.13 |
| 10 | Bosera Growth Preferred Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 23.58 | 0.13 |
5. Concept Sectors
- Generic Drugs
- Innovative Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- Science and Technology Innovation Board Biotech
- Science and Technology Innovation 200
- SSE 580
Remarks
- Data update date: 2025-11-10
- Data source: Public market information